None of those genes had significantly higher alteration prevalence post-AI or post-chemotherapy, and the post-treatment prevalence was highest in the AI+CDK4/6i cohort, reinforcing the specific and profound impact of CDK4/6i on the tumor genomic landscape. The gene discussed is CDK4; the disease is neoplasm.